| scholarly article | Q13442814 |
| P50 | author | Hiroaki Kataoka | Q60976407 |
| P2093 | author name string | Takahiro Nagai | |
| Naoki Terada | |||
| Yoshinobu Toda | |||
| Shoichiro Mukai | |||
| Toshiyuki Kamoto | |||
| Hiromasa Sakamoto | |||
| Noboru Shibasaki | |||
| Satoru Sugie | |||
| Koji Yamasaki | |||
| Kozue Nakahara | |||
| Toyoharu Kamibeppu | |||
| P2860 | cites work | Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma | Q46248263 |
| Expression of serine protease matriptase in renal cell carcinoma: correlation of tissue microarray immunohistochemical expression analysis results with clinicopathological parameters | Q46963498 | ||
| Hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2): Emerging key players in epithelial integrity and cancer. | Q50068598 | ||
| Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial. | Q50139906 | ||
| Expression of human kallikrein 1-related peptidase 4 (KLK4) and MET phosphorylation in prostate cancer tissue: immunohistochemical analysis | Q53220940 | ||
| Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma. | Q55043279 | ||
| Hepatocyte growth factor as mitogen, motogen and morphogen, and its roles in organ regeneration | Q71943753 | ||
| Hepatocyte growth factor activator inhibitor, a novel Kunitz-type serine protease inhibitor | Q24322087 | ||
| Bone Metastasis from Renal Cell Carcinoma | Q26747493 | ||
| Selective Allosteric Inhibition of MMP9 Is Efficacious in Preclinical Models of Ulcerative Colitis and Colorectal Cancer | Q27306938 | ||
| Quantitative real-time RT-PCR data analysis: current concepts and the novel "gene expression's CT difference" formula | Q28263575 | ||
| Sunitinib versus interferon alfa in metastatic renal-cell carcinoma | Q28282757 | ||
| High expression of the Met receptor in prostate cancer metastasis to bone | Q34163761 | ||
| Drug development of MET inhibitors: targeting oncogene addiction and expedience | Q34782774 | ||
| Matriptase: potent proteolysis on the cell surface | Q34809525 | ||
| Matriptase and MET are prominently expressed at the site of bone metastasis in renal cell carcinoma: immunohistochemical analysis | Q34854941 | ||
| HAI-2 suppresses the invasive growth and metastasis of prostate cancer through regulation of matriptase. | Q35041020 | ||
| The intricate role of CXCR4 in cancer | Q35067624 | ||
| Roles of hepatocyte growth factor (HGF) activator and HGF activator inhibitor in the pericellular activation of HGF/scatter factor | Q35144580 | ||
| Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. | Q35252908 | ||
| The MET receptor tyrosine kinase in invasion and metastasis | Q36868644 | ||
| Renal cell carcinoma bone metastasis--elucidating the molecular targets | Q36928033 | ||
| Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206 | Q37117085 | ||
| Targeting the Met signaling pathway in renal cancer. | Q37331862 | ||
| Brain metastasis in renal cancer patients: metastatic pattern, tumour-associated macrophages and chemokine/chemoreceptor expression | Q37559001 | ||
| C-met inhibition blocks bone metastasis development induced by renal cancer stem cells. | Q37564471 | ||
| Differential Tumorigenic Potential and Matriptase Activation between PDGF B versus PDGF D in Prostate Cancer | Q37593021 | ||
| Matriptase-mediated cleavage of EpCAM destabilizes claudins and dysregulates intestinal epithelial homeostasis | Q37610695 | ||
| MET signalling: principles and functions in development, organ regeneration and cancer | Q37811895 | ||
| Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny | Q38021967 | ||
| Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. | Q38859789 | ||
| Strong expression association between matriptase and its substrate prostasin in breast cancer | Q39523621 | ||
| Presence of phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor progression and survival in patients with conventional renal cell carcinoma | Q40242701 | ||
| Establishment and characterization of a human renal carcinoma cell line MRT-1, with special reference to the production of serine proteinase inhibitors | Q41365940 | ||
| A direct role for Met endocytosis in tumorigenesis. | Q42809894 | ||
| Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and beta-catenin/Wnt pathways. | Q43115646 | ||
| Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma | Q43299263 | ||
| Microenvironment-derived HGF overcomes genetically determined sensitivity to anti-MET drugs. | Q44843363 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 6 | |
| P921 | main subject | phosphorylation | Q242736 |
| P577 | publication date | 2018-06-08 | |
| P1433 | published in | Cancers | Q27722963 |
| P1476 | title | Dysregulated HAI-2 Plays an Important Role in Renal Cell Carcinoma Bone Metastasis through Ligand-Dependent MET Phosphorylation. | |
| P478 | volume | 10 |
Search more.